search
Back to results

Personalized Prevotella sp. and Butyrate Enriching Diet (PPBe) (PPBe)

Primary Purpose

Pregnancy, Food Hypersensitivity

Status
Unknown status
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Personalized Prevotella sp. and butyrate enriching diet guidelines
Sponsored by
Universiti Sains Malaysia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pregnancy

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Malaysian and of the Malay ethnicity
  • Living in Kelantan for at least 5 years
  • Age 18 to 40 years
  • The lower limit of ≥16th weeks and the upper limit of <20th week of gestation during enrollment to allow at least 20 weeks of dietary intervention prior to delivery. The gestational age was based on the last menstrual period (LMP) or early ultrasound examination
  • Singleton pregnancy
  • History of personal and family history of allergy (presence of reported or doctor-diagnosed allergic disease including asthma, eczema, food allergy, or allergy rhinitis) in participants, their partners or in their previous child or pregnancy.
  • In attendance of antenatal clinic at Hospital USM or Klinik Kesihatan (Kota Bharu/Kubang Kerian/Pengkalan Chepa)
  • Living area within 10 km radius of Kota Bharu, Kelantan
  • Consent to participate

Exclusion Criteria:

  • Significant present or having past medical history of chronic disease for example bowel, cancer disease, systemic lupus erythematosus (SLE), chronic kidney disease, heart failure, stroke, haematological malignancy, and chronic obstructive pulmonary disease.
  • Significant psychiatric history including major depression and other psychotic disorders.
  • Significant present or past surgical history including bowel surgeries
  • Significant presence of doctor-diagnosed short intestinal bacteria overgrowth (SIBO).
  • Taking any medications which may disturb the gut microbiota or intestinal function, for example, antibiotics for the past 3 months, immunosuppressive drugs, opiates, anticoagulants and etc.
  • Those who plan to move out from Kelantan after delivery which may affect the follow-up.
  • Those who follow a vegetarian diet will also be excluded from participating.

Sites / Locations

  • Hospital Universiti Sains MalaysiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Usual diet

PPBe Diet

Arm Description

Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.

Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.

Outcomes

Primary Outcome Measures

Maternal Prevotella and butyrate level during pregnancy and infants food allergy
Maternal Prevotella and butyrate level will be compared between groups and correlate with the incidence of infant's food allergy at 12 months of age.

Secondary Outcome Measures

Infant's gut microbiota and butyrate level and infant's food allergy
Infant's early gut microbiota and butyrate level on day-7 dan 3-month will be correlate with the incidence of food's allergy at 12-months
Immune function, gut barrier and infant's food allergy development
Infant's immune function (measured by interleukin-10/IL-10, and transforming growth factor-beta/TGF-B) and gut barrier (intestinal fatty acid binding protein/I-FABP) will be measured at 12-months of ages and further correlate with infant's gut microbiota and butyrate level to investigate the underlying mechanism that could explain food allergy development.
Maternal gut microbiota and butyrate level during pregnancy and infant's immune function and gut barrier development
Infant's immune function (measured by interleukin-10/IL-10, and transforming growth factor-beta/TGF-B) and gut barrier (intestinal fatty acid binding protein/I-FABP) will be measured at 12-months of ages and further correlate with maternal gut microbiota and butyrate level during pregnancy to investigate the underlying mechanism that could explain food allergy development

Full Information

First Posted
May 9, 2021
Last Updated
September 28, 2021
Sponsor
Universiti Sains Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT04885959
Brief Title
Personalized Prevotella sp. and Butyrate Enriching Diet (PPBe)
Acronym
PPBe
Official Title
Personalized Prevotella sp. and Butyrate Enriching Diet for Pregnant Mother and The Risk of Infant's Food Allergy: A Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
January 31, 2023 (Anticipated)
Study Completion Date
February 28, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Sains Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The research aims to elucidate a specially-designed personalized diet that will increase gut colonization of Prevotella sp. and butyrate levels in pregnant mothers and the benefits in reducing infant's food allergy development.
Detailed Description
After being informed about the study and potential risk, all patients giving written informed consent will go one week screening period to assess for study eligibility prior to enrollment. At week 0, single-blind randomization (subject and health care providers except for principal investigator) will be conducted and participant will be randomized into two groups namely; the control group and the intervention group. The control group will receive standard dietary counselling on a healthy pregnancy diet. Meanwhile, the intervention group will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate. The trial will be in 20 weeks duration during pregnancy and additional 12-months follow up for the delivered infants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Food Hypersensitivity

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
92 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Usual diet
Arm Type
Placebo Comparator
Arm Description
Participants are subjected to received general dietary advice from attended nurses or physician during their antenatal visits.
Arm Title
PPBe Diet
Arm Type
Experimental
Arm Description
Participants will receive dietary intervention which is tailored to the study objective to increase targeted bacteria of Prevotella sp and the short-chain fatty acids namely butyrate.
Intervention Type
Behavioral
Intervention Name(s)
Personalized Prevotella sp. and butyrate enriching diet guidelines
Intervention Description
specially design dietary guidelines with biomarkers monitoring
Primary Outcome Measure Information:
Title
Maternal Prevotella and butyrate level during pregnancy and infants food allergy
Description
Maternal Prevotella and butyrate level will be compared between groups and correlate with the incidence of infant's food allergy at 12 months of age.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Infant's gut microbiota and butyrate level and infant's food allergy
Description
Infant's early gut microbiota and butyrate level on day-7 dan 3-month will be correlate with the incidence of food's allergy at 12-months
Time Frame
12 months
Title
Immune function, gut barrier and infant's food allergy development
Description
Infant's immune function (measured by interleukin-10/IL-10, and transforming growth factor-beta/TGF-B) and gut barrier (intestinal fatty acid binding protein/I-FABP) will be measured at 12-months of ages and further correlate with infant's gut microbiota and butyrate level to investigate the underlying mechanism that could explain food allergy development.
Time Frame
12 months
Title
Maternal gut microbiota and butyrate level during pregnancy and infant's immune function and gut barrier development
Description
Infant's immune function (measured by interleukin-10/IL-10, and transforming growth factor-beta/TGF-B) and gut barrier (intestinal fatty acid binding protein/I-FABP) will be measured at 12-months of ages and further correlate with maternal gut microbiota and butyrate level during pregnancy to investigate the underlying mechanism that could explain food allergy development
Time Frame
12 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Pregnant women
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Malaysian and of the Malay ethnicity Living in Kelantan for at least 5 years Age 18 to 40 years The lower limit of ≥16th weeks and the upper limit of <20th week of gestation during enrollment to allow at least 20 weeks of dietary intervention prior to delivery. The gestational age was based on the last menstrual period (LMP) or early ultrasound examination Singleton pregnancy History of personal and family history of allergy (presence of reported or doctor-diagnosed allergic disease including asthma, eczema, food allergy, or allergy rhinitis) in participants, their partners or in their previous child or pregnancy. In attendance of antenatal clinic at Hospital USM or Klinik Kesihatan (Kota Bharu/Kubang Kerian/Pengkalan Chepa) Living area within 10 km radius of Kota Bharu, Kelantan Consent to participate Exclusion Criteria: Significant present or having past medical history of chronic disease for example bowel, cancer disease, systemic lupus erythematosus (SLE), chronic kidney disease, heart failure, stroke, haematological malignancy, and chronic obstructive pulmonary disease. Significant psychiatric history including major depression and other psychotic disorders. Significant present or past surgical history including bowel surgeries Significant presence of doctor-diagnosed short intestinal bacteria overgrowth (SIBO). Taking any medications which may disturb the gut microbiota or intestinal function, for example, antibiotics for the past 3 months, immunosuppressive drugs, opiates, anticoagulants and etc. Those who plan to move out from Kelantan after delivery which may affect the follow-up. Those who follow a vegetarian diet will also be excluded from participating.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
NUR-FAZIMAH SAHRAN
Phone
0136004484
Email
nfazimah_sahran@usm.my
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
NUR-FAZIMAH SAHRAN
Organizational Affiliation
Universiti Sains Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universiti Sains Malaysia
City
Kota Bharu
State/Province
Kelantan
ZIP/Postal Code
16150
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
NUR-FAZIMAH SAHRAN
Phone
0136004484
Email
nfazimah_sahran@usm.my
First Name & Middle Initial & Last Name & Degree
Yeong Yeh Lee
Email
yylee@usm.my

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is not a plan to make IPD available

Learn more about this trial

Personalized Prevotella sp. and Butyrate Enriching Diet (PPBe)

We'll reach out to this number within 24 hrs